mAb-cycPYY

mAb-cycPYY is a long-acting conjugate drug candidate designed for the treatment of obesity and metabolic diseases. It consists of a monoclonal antibody (mAb) chemically linked to a stabilized, cyclic analog of peptide YY3–36 (cycPYY), which is engineered for enhanced resistance to proteolytic degradation and improved pharmacokinetics. The mechanism of action involves potent and selective agonism at the neuropeptide Y2 receptor (NPY2R), leading to reduced food intake, body weight loss, and improved glucose homeostasis in preclinical models. The drug has demonstrated robust anorectic efficacy with minimal gastrointestinal side effects in animal studies, suggesting potential as an anti-obesity therapy—especially in combination with GLP-1 receptor agonists[1][2].